Article

Candidate Pathways for Promoting Differentiation or Quiescence of Oligodendrocyte Progenitor-like Cells in Glioma.

Authors' Affiliations: Departments of Genetics and Psychiatry, Washington University, St. Louis, Missouri; Department of Neurosurgery, Brain Tumor Center, Department of Cancer Biology and Genetics, Department of Neurology, Department of Surgery, Memorial Sloan Kettering Cancer Center; and The GENSAT project, Laboratory of Molecular Biology, The Rockefeller University, New York, NY.
Cancer Research (impact factor: 7.86). 08/2012; 72(18):4856-68. DOI:10.1158/0008-5472.CAN-11-2632 pp.4856-68
Source: PubMed

ABSTRACT Platelet-derived growth factor receptor alpha-positive oligodendrocyte progenitor cells (OPC) located within the mature central nervous system may remain quiescent, proliferate, or differentiate into oligodendrocytes. Human glioblastoma multiforme tumors often contain rapidly proliferating oligodendrocyte lineage transcription factor 2 (Olig2)-positive cells that resemble OPCs. In this study, we sought to identify candidate pathways that promote OPC differentiation or quiescence rather than proliferation. Gene expression profiling conducted in both normal murine OPCs and highly proliferative Olig2-positive glioma cells identified all the transcripts associated with the highly proliferative state of these cells and showed that among the various cell types found within the brain, Olig2-positive tumor cells are most similar to OPCs. We then subtracted OPC transcripts found in tumor samples from those found in normal brain samples and identified 28 OPC transcripts as candidates for promoting differentiation or quiescence. Systematic analysis of human glioma data revealed that these genes have similar expression profiles in human tumors and were significantly enriched in genomic deletions, suggesting an antiproliferative role. Treatment of primary murine glioblastoma cells with agonists of one candidate gene, Gpr17, resulted in a decreased number of neurospheres. Together, our findings show that comparison of the molecular phenotype of progenitor cells in tumors to the equivalent cells in the normal brain represents a novel approach for the identification of targeted therapies. Cancer Res; 72(18); 4856-68. ©2012 AACR.

0 0
 · 
0 Bookmarks
 · 
48 Views

Keywords

Cancer Res
 
candidate gene
 
decreased number
 
Gene expression profiling
 
genes
 
genomic deletions
 
Human glioblastoma multiforme tumors
 
human glioma data
 
mature central nervous system
 
normal brain
 
normal brain samples
 
normal murine OPCs
 
Olig2-positive tumor cells
 
Platelet-derived growth factor receptor alpha-positive oligodendrocyte progenitor cells
 
primary murine glioblastoma cells
 
proliferative Olig2-positive glioma cells
 
promote OPC differentiation
 
resemble OPCs
 
Systematic analysis
 
various cell types